IL310400A - Cycloalkene derivative regulator, preparation method therefor, and application thereof - Google Patents

Cycloalkene derivative regulator, preparation method therefor, and application thereof

Info

Publication number
IL310400A
IL310400A IL310400A IL31040024A IL310400A IL 310400 A IL310400 A IL 310400A IL 310400 A IL310400 A IL 310400A IL 31040024 A IL31040024 A IL 31040024A IL 310400 A IL310400 A IL 310400A
Authority
IL
Israel
Prior art keywords
alkyl
cycloalkyl
group
methyl
aryl
Prior art date
Application number
IL310400A
Other languages
English (en)
Hebrew (he)
Inventor
Yidong Su
Xiaofeng Mao
Jun Wang
Xiaohan Zhou
Wensheng Yu
Original Assignee
Shanghai Hansoh Biomedical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Yidong Su
Xiaofeng Mao
Jun Wang
Xiaohan Zhou
Wensheng Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Yidong Su, Xiaofeng Mao, Jun Wang, Xiaohan Zhou, Wensheng Yu filed Critical Shanghai Hansoh Biomedical Co Ltd
Publication of IL310400A publication Critical patent/IL310400A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL310400A 2021-08-04 2022-08-03 Cycloalkene derivative regulator, preparation method therefor, and application thereof IL310400A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110892791 2021-08-04
CN202111322097 2021-11-09
CN202210041958 2022-01-14
CN202210540040 2022-05-17
PCT/CN2022/110017 WO2023011539A1 (zh) 2021-08-04 2022-08-03 环烯类衍生物调节剂、其制备方法和应用

Publications (1)

Publication Number Publication Date
IL310400A true IL310400A (en) 2024-03-01

Family

ID=85155248

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310400A IL310400A (en) 2021-08-04 2022-08-03 Cycloalkene derivative regulator, preparation method therefor, and application thereof

Country Status (11)

Country Link
US (1) US20240360109A1 (https=)
EP (1) EP4382525A4 (https=)
JP (1) JP2024529527A (https=)
KR (1) KR20240042624A (https=)
CN (1) CN117751110A (https=)
AU (1) AU2022321506A1 (https=)
CA (1) CA3227366A1 (https=)
IL (1) IL310400A (https=)
MX (1) MX2024001331A (https=)
TW (1) TW202321227A (https=)
WO (1) WO2023011539A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3188891A1 (en) 2020-09-01 2022-01-13 Fanglong Yang Fused imidazole derivative, preparation method therefor, and medical use thereof
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
TW202434574A (zh) * 2023-02-02 2024-09-01 大陸商江蘇豪森藥業集團有限公司 一種環烯類化合物的鹽、晶型及其製備方法和應用
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025247390A1 (zh) * 2024-05-31 2025-12-04 福佑泰生物制药公司 可用作glp-1r激动剂的杂双环化合物
WO2025252201A1 (zh) * 2024-06-07 2025-12-11 江苏豪森药业集团有限公司 一种环烯类衍生物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022742A1 (en) * 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
KR102314286B1 (ko) * 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
DK3806855T5 (da) * 2018-06-15 2023-05-22 Pfizer GLP-1-receptoragonister og anvendelser deraf
MA54555A (fr) * 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
EP3953344A4 (en) * 2019-04-12 2023-08-09 Qilu Regor Therapeutics Inc. GLP-IR AGONISTS AND THEIR USES
WO2021018023A1 (zh) * 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
EP4048664A1 (en) * 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021096284A1 (ko) * 2019-11-15 2021-05-20 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
TW202206429A (zh) * 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
CA3192601A1 (en) * 2020-08-21 2022-02-24 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CA3188891A1 (en) * 2020-09-01 2022-01-13 Fanglong Yang Fused imidazole derivative, preparation method therefor, and medical use thereof
EP4229050A4 (en) * 2020-10-13 2024-12-11 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN114805336B (zh) * 2021-01-20 2026-04-14 江苏恒瑞医药股份有限公司 稠合咪唑类化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2023011539A1 (zh) 2023-02-09
EP4382525A4 (en) 2025-07-16
US20240360109A1 (en) 2024-10-31
CA3227366A1 (en) 2023-02-09
JP2024529527A (ja) 2024-08-06
CN117751110A (zh) 2024-03-22
KR20240042624A (ko) 2024-04-02
MX2024001331A (es) 2024-04-19
EP4382525A1 (en) 2024-06-12
AU2022321506A1 (en) 2024-02-01
TW202321227A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
IL310400A (en) Cycloalkene derivative regulator, preparation method therefor, and application thereof
CN115244056B (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN113493447B (zh) Glp-1受体激动剂
CN117362283B (zh) Glp-1受体激动剂及其组合物和用途
US11136324B2 (en) Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors
WO2022228490A1 (zh) 多环类衍生物调节剂、其制备方法和应用
CN105518008B (zh) 氨基吡喃环衍生物及其组合物和应用
EP2358371B1 (en) P2x3, receptor antagonists for treatment of pain
TW202214610A (zh) ６－側氧－３，６－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
CN101646665A (zh) 用于治疗糖尿病的1-(1-苄基哌啶-4-基)苯并咪唑-5-羧酸衍生物
WO2021244634A1 (zh) 咪唑并吡啶类化合物及其用途
CN113166135A (zh) 苯并噻吩类衍生物调节剂、其制备方法和应用
CN117986264A (zh) 苯并含氮多环类衍生物调节剂及其制备方法和应用
EP4168400A1 (en) Small molecule modulators of il-17
CN118420603A (zh) 一种环烯类化合物的氨丁三醇盐晶型及其制备方法和用途
WO2024160271A1 (zh) 一种环烯类化合物的盐、晶型及其制备方法和应用
CN101679260A (zh) 4,4-二取代的哌啶衍生物
CN119431369A (zh) 含氮杂芳环类衍生物调节剂、其制备方法和应用
EA052008B1 (ru) Регулятор на основе циклоалкенового производного, способ его получения и его применение
WO2025261454A1 (zh) 一种含氮大环化合物衍生物调节剂及其制备方法和应用
WO2025096658A1 (en) Compositions and inhibitors of polrmt
CN119841812A (zh) 四氢异喹啉类化合物、其制备方法及其在医药上的应用
EA049148B1 (ru) Агонист рецептора glp-1, его композиция и его применение
HK40047618A (en) Benzothiophene derivative regulator, preparation method therefor and use thereof
HK40003699B (zh) 酰胺类衍生物抑制剂及其制备方法和应用